61 results
8-K
EX-99.1
LBPH
Longboard Pharmaceuticals, Inc.
1 Jul 24
Regulation FD Disclosure
9:15am
for the DEE community. Most of those living with DEEs do not have access to novel medications, nor have they had the opportunity to participate in trials … and pleased that there is a move towards increased equity and access for underserved patients and families to clinical trials and potential novel
8-K
EX-99.1
LBPH
Longboard Pharmaceuticals, Inc.
10 Jun 24
Regulation FD Disclosure
9:05am
and transition to our Expanded Access Program,” Dr. Kaye continued. “With an End of Phase 2 meeting scheduled this summer, we remain on track to initiate our … of patients to progress in the OLE Study and transition to an expanded access program, and their design and characteristics; Longboard’s ability to develop
PRE 14A
ozqi7duww
28 Mar 24
Preliminary proxy
4:36pm
8-K
EX-1.1
4vf73tjye4knvbcp1
4 Jan 24
Other Events
4:51pm
424B5
4nzdkox
4 Jan 24
Prospectus supplement for primary offering
4:48pm
424B5
3jghqgi
2 Jan 24
Prospectus supplement for primary offering
4:54pm
8-K
EX-99.1
azbp7ke1rpfgx
2 Nov 23
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
9dbympss j74y7
11 Oct 23
Regulation FD Disclosure
9:26am
8-K
EX-3.1
ni8p9
22 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:21pm
8-K
EX-99.1
nsnvqo8i9dj64f
23 Aug 23
Enrolled 52 participants with Developmental and Epileptic Encephalopathies (DEEs) into the PACIFIC Study
8:46am
424B5
80hg gq8v0qff06
4 Aug 23
Prospectus supplement for primary offering
4:20pm